Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Mar;47(3):353–359. doi: 10.1038/bjc.1983.53

Serotherapy of L1210 murine leukaemia--reasons for ineffectiveness of in vivo treatment by L.1 monoclonal antibody.

C Testorelli, G Canti, P Franco, A Goldin, A Nicolin
PMCID: PMC2011306  PMID: 6830686

Abstract

A monoclonal antibody (L.1), reacting in vitro specifically with L1210 leukaemia cells in a complement-dependent cytotoxicity assay (CDC), has been exploited for serotherapy studies. Different regiments of L.1 treatment of CD2F1 mice bearing the semi-syngeneic L1210 leukaemia did not prolong the life span of tumor-bearing animals. Moreover, the administration of L.1 did not enhance the antitumour effects of cyclophosphamide. Studies of in vivo localization showed that L.1 was able to bind specifically to L1210 leukaemic cells, although 30-40% of the cells remained negative. The presence of L.1 in mouse blood was demonstrated up to 15 days after the inoculation. On the other hand, in vivo administration of L.1 was probably accompanied by loss of the cytotoxic activity, perhaps through a mechanism of complement inactivation, since the presence of undiluted normal mouse serum in a CDC assay inhibited the cytotoxic activity of L.1. Moreover, serum from L.1-treated mice did not display any cytotoxic activity, although the presence of the antibody could be demonstrated by indirect immunofluorescence. Shedding of the antigen defined by L.1 was probably not responsible for the failure of the serotherapy, since the L.1 neutralizing antigen could be found in body fluids only long after the start of therapy.

Full text

PDF
353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball E. D., Kadushin J. M., Schacter B., Fanger M. W. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells. J Immunol. 1982 Mar;128(3):1476–1481. [PubMed] [Google Scholar]
  2. Bernstein I. D., Tam M. R., Nowinski R. C. Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science. 1980 Jan 4;207(4426):68–71. doi: 10.1126/science.6965328. [DOI] [PubMed] [Google Scholar]
  3. Gunn B., Embleton M. J., Middle J. G., Baldwin R. W. Monoclonal antibody against a naturally occurring rat mammary carcinoma. Int J Cancer. 1980 Sep 15;26(3):325–330. doi: 10.1002/ijc.2910260311. [DOI] [PubMed] [Google Scholar]
  4. Herlyn D. M., Koprowski H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer. 1981 Jun 15;27(6):769–774. doi: 10.1002/ijc.2910270607. [DOI] [PubMed] [Google Scholar]
  5. Iwaki Y., Kasai M. K., Terasaki P. I., Bernoco D., Park M. S., Cicciarelli J., Heintz R., Saxton R. E., Burk M. W., Morton D. L. Monoclonal antibody against A1 Lewis d antigen produced by the hybridoma immunized with a pulmonary carcinoma. Cancer Res. 1982 Feb;42(2):409–411. [PubMed] [Google Scholar]
  6. Kirch M. E., Hammerling U. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells. J Immunol. 1981 Aug;127(2):805–810. [PubMed] [Google Scholar]
  7. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  8. Metzgar R. S., Borowitz M. J., Jones N. H., Dowell B. L. Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med. 1981 Oct 1;154(4):1249–1254. doi: 10.1084/jem.154.4.1249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 1981 Aug 1;2(8240):226–230. doi: 10.1016/s0140-6736(81)90475-x. [DOI] [PubMed] [Google Scholar]
  10. Ozato K., Mayer N., Sachs D. H. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol. 1980 Feb;124(2):533–540. [PubMed] [Google Scholar]
  11. Raso V., Ritz J., Basala M., Schlossman S. F. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res. 1982 Feb;42(2):457–464. [PubMed] [Google Scholar]
  12. Ritz J., Pesando J. M., Notis-McConarty J., Lazarus H., Schlossman S. F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 7;283(5747):583–585. doi: 10.1038/283583a0. [DOI] [PubMed] [Google Scholar]
  13. Ritz J., Pesando J. M., Sallan S. E., Clavell L. A., Notis-McConarty J., Rosenthal P., Schlossman S. F. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul;58(1):141–152. [PubMed] [Google Scholar]
  14. Scheinberg D. A., Strand M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res. 1982 Jan;42(1):44–49. [PubMed] [Google Scholar]
  15. Sears H. F., Herlyn D., Herlyn M., Steplewski Z., Grotzinger P., Koprowski H. Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer. 1982 Mar 15;49(6):1231–1235. doi: 10.1002/1097-0142(19820315)49:6<1231::aid-cncr2820490626>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  16. Testorelli C., Morelli S., Goldin A., Nicolin A. Characterization of a monoclonal antibody to L1210 leukaemia. Br J Cancer. 1982 Mar;45(3):395–402. doi: 10.1038/bjc.1982.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Trowbridge I. S., Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1175–1179. doi: 10.1073/pnas.79.4.1175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wright P. W., Bernstein I. D. Serotherapy of malignant disease. Prog Exp Tumor Res. 1980;25:140–162. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES